Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females greater than or equal to (≥) 18 years of age, with histologically-confirmed HER2-positive breast cancer
Metastatic breast cancer, with progression on trastuzumab-based therapy as last treatment for metastatic disease
Less than or equal to (≤) 3 chemotherapy regimens prior to study entry
Last trastuzumab dose ≤9 weeks before study entry for participants receiving pertuzumab + trastuzumab, and ≥4 weeks for participants receiving pertuzumab monotherapy
Left ventricular ejection fraction ≥55% at study entry
You may not be if
Previous treatment with an anti-cancer vaccine or any targeted therapy other than trastuzumab
Brain metastases
History of any cardiac adverse event related to trastuzumab therapy
Any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix
Clareo Health | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
